阿托伐他丁联合通心络对冠心病患者血液流变学及炎性因子的影响被引量：14

Effect of atorvastatin combined with Tongxinluo on hemorheology and inflammatory factors in patients with coronary heart disease

下载PDF

导出

摘要目的:分析阿托伐他丁联合通心络对冠心病患者血液流变学及炎性因子的影响。方法:选择在本院接受治疗的42例冠心病患者并随机分为观察组及对照组各21例,对照组接受常规治疗,观察组接受常规治疗+阿托伐他丁联合通心络治疗,对比两组治疗后的心功能、血粘度以及血清中脂质代谢指标、炎症反应指标。结果:治疗后3个疗程,观察组治疗后的EF值、E/A比值均显著高于对照组,全血高切黏度、全血低切黏度、血浆黏度均显著低于对照组(P<0.05);观察组治疗后的血清TC、TG、LDLC、Leptin、Resistin、Visfatin、IL-18、TNF-α、sTREM-1、MMP-9含量显著低于对照组(P<0.05),IL-4、IL-10、IL-37、MFG-E8含量显著高于对照组(P<0.05)。结论:阿托伐他丁联合通心络可优化冠心病病情,在优化血液流变学及炎症反应等方面发挥积极作用。 Objective：To analyze the effects of atorvastatin combined with Tongxinluo on hemorheology and inflammatory factors in patients with coronary heart disease.Methods：A total of 42 patients with coronary heart disease treated in our hospital were selected and randomly divided into observation group and control group（n=21）,control group received routine therapy,observation group received routine therapy＋ atorvastatin combined with Tongxinluo therapy,and then cardiac function,blood viscosity as well as serum lipid metabolism indexes and inflammation indexes were compared between the two groups after treatment.Results：After 3courses of treatment,EF value and E/A ratio of observation group were significantly higher than those of control group,and whole blood high shear viscosity,whole blood low shear viscosity and plasma viscosity were significantly lower than those of control group;serum TC,TG,LDL-C,Leptin,Resistin,Visfatin,IL-18,TNF-α,sTREM-1and MMP-9levels of observation group after treatment were significantly lower than those of control group,and IL-4,IL-10,IL-37 and MFG-E8 levels were significantly higher than those of control group.Conclusion：Atorvastatin combined with Tongxinluo can optimize the state of coronary heart disease,and it plays a positive role in optimizing hemorheology,inflammation and other aspects.

作者任玉环

机构地区江苏省东海县中医院内科

出处《海南医学院学报》 CAS 2016年第20期2373-2375,2379,共4页 Journal of Hainan Medical University

基金江苏省中医药科技项目(YB2015119)~~

关键词冠心病阿托伐他丁通心洛血液流变学 Coronary heart disease Atorvastatin Tongxinluo Hemorheology

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献16

1Puri R,Nissen SE,Shao M,et al.Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome:insights from study of coronary atheroma by intravascular ultrasound:effect of rosuvastatin versus atorvastatin[J].Arterioscler Thromb Vasc Biol,2014,34(11):2465-2472.
2粟治洲,吕建峰,刘波,迟路湘.不同剂量他汀治疗急性冠脉综合征患者急性期疗效观察[J].第三军医大学学报,2015,37(1):60-63. 被引量：14
3Zhang H,Liu M,Ren T,et al.Associations between carotid artery plaque score,carotid hemodynamics and coronary heart disease[J].Int J Environ Res Public Health,2015,12(11):14275-14284.
4李巍,马波江.硝苯地平缓释片对高血压合并冠心病患者血液流变学的影响[J].中国生化药物杂志,2015,35(12):163-164. 被引量：24
5Matusiak A,Chaubiński M,Broncel M,et al.Putative consequences of exposure to Helicobacter pylori infection in patients with coronary heart disease in terms of humoral immune response andinflammation[J].Arch Med Sci,2016,12(1):45-54.
6O'Neal WT,Soliman EZ,Howard G,et al.Inflammation and hemostasis in atrial fibrillation and coronary heart disease:The REasons for geographic and racial differences in stroke study[J].Atherosclerosis,2015,243(1):192-197.
7丁美琳,陈龙,龚迎迎.通心络上调CXCR4信号通路增强冠心病患者血管内皮祖细胞功能[J].广东医学,2015,36(24):3862-3865. 被引量：12
8Navarro-Millán I,Yang S,DuVall SL,et al.Association of hyperlipidaemia,inflammation and serological status and coronary heart diseaseamong patients with rheumatoid arthritis:data from the national veterans health administration[J].Ann Rheum Dis,2016,75(2):341-347.
9Adamiak P,La,cka K.Adipose tissue,adipokines and aging[J].Pol MerkurLekarski,2016,40(236):122-128.
10Luan B,Goodarzi MO,Phillips NG,et al.Leptin-mediated increases in catecholamine signaling reduce adipose tissue inflammation via activation of macrophage HDAC4[J].Cell Metab,2014,19(6):1058-1065.

二级参考文献40

1吕程,黄紫红,刘纲毅.冠心病患者血液流变学及血浆D-二聚体的临床应用[J].中国血液流变学杂志,2008,18(3). 被引量：4
2祁贺栋.冠心病时血液流变学指标变化及临床意义[J].现代检验医学杂志,2005,20(6):76-77. 被引量：4
3Delahoy P J, Magliano D J, Webb K, et al. The relationship between reduction in low-density lipoprotein cholesterol by st- atins and reduction in risk of cardiovascular outcomes : an up- dated meta-analysis[J]. Clin Ther, 2009, 31(2): 236- 244.
4Stone N J, Robinson J G, Lichtenstein A H, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults : a report of the American College of Cardiology/American Heart Associa- tion Task Force on Practice Guidelines [ J ]. J Am Coll Cardi- ol, 2014, 63(25 Pt B) : 2889 -2934.
5Sniderman A, Thanassoulis G, Couture P, et al. Is lower and lower better and better9 A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analy- sis for low-density lipoprotein lowering [ J ]. J Clin Lipidol, 2012, 6(4): 303-309.
6Study of the Effectiveness of Additional Reductions in Choles- terol and Homocysteine (SEARCH) Collaborative Group, Ar- mitage J, Bowman L, et al. Intensive lowering of LDL choles- terol with 80 mg versus 20 mg simvastatin daily in 12, 064 survivors of myocardial infarction: a double-blind randomised trial[J]. Lancet, 2010, 376(9753): 1658- 1669.
7Huang F, Huang J P, Yin R X, et al. Circulating microR- NAs as potential biomarkers for the early diagnosis of acute myocardial infarction: promises and challenges [ J ]. Int J Car- diol, 2013, 168(4): 4510-4511.
8Cholesterol Treatment Trialists' (CTT) Collaborators, Mihay- lova B, Emberson J, et al. The effects of lowering LDL cho- lesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials[J]. Lancet, 2012, 380(9841): 581 -590.
9Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease [J]. J Am Coll Cardiol, 2013, 61(4): 427 -436.
10Catapano A L, Chapman J, Wiklund O, et al. The new joint EAS/ESC guidelines for the management of dyslipidae- mias [ J ]. Atherosclerosis, 2011, 217 ( 1 ) : 1.